These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27616561)

  • 21. Emerging treatment strategies and potential therapeutic targets in primary Sjögren's syndrome.
    Becker H; Pavenstaedt H; Willeke P
    Inflamm Allergy Drug Targets; 2010 Mar; 9(1):10-9. PubMed ID: 19906008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary Sjögren's syndrome at a glance today.
    Youinou P; Pers JO
    Joint Bone Spine; 2015 Mar; 82(2):75-6. PubMed ID: 25619154
    [No Abstract]   [Full Text] [Related]  

  • 23. Primary Sjogren's syndrome: current and prospective therapies.
    Thanou-Stavraki A; James JA
    Semin Arthritis Rheum; 2008 Apr; 37(5):273-92. PubMed ID: 17714766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current and future therapies for primary Sjögren syndrome.
    Seror R; Nocturne G; Mariette X
    Nat Rev Rheumatol; 2021 Aug; 17(8):475-486. PubMed ID: 34188206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
    Saraux A
    Autoimmun Rev; 2010 Jul; 9(9):609-14. PubMed ID: 20452466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Diagnosis and Treatment of Sjögren's Syndrome.
    Stefanski AL; Tomiak C; Pleyer U; Dietrich T; Burmester GR; Dörner T
    Dtsch Arztebl Int; 2017 May; 114(20):354-361. PubMed ID: 28610655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognosis of patients with primary Sjögren's syndrome].
    Brito-Zerón P; Ramos-Casals M
    Med Clin (Barc); 2008 Feb; 130(3):109-15. PubMed ID: 18261383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-CD20 antibody in primary Sjögren's syndrome management.
    Chen S; Liu Y; Shi G
    Curr Pharm Biotechnol; 2014; 15(6):535-41. PubMed ID: 25213362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-17-producing double-negative T cells are expanded in the peripheral blood, infiltrate the salivary gland and are partially resistant to corticosteroid therapy in patients with Sjögren's syndrome.
    Alunno A; Bistoni O; Bartoloni Bocci E; Caterbi S; Bigerna B; Pucciarini A; Tabarrini A; Mannucci R; Beghelli D; Falini B; Gerli R
    Reumatismo; 2013 Oct; 65(4):192-8. PubMed ID: 24192564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agranulocytosis and mixed-type autoimmune hemolytic anemia in primary sjögren's syndrome: a case report and review of the literature.
    Qiao L; Chen J; Leng XM; Zhang W; Han B; Zhao Y; Zeng XF
    Int J Rheum Dis; 2016 Dec; 19(12):1351-1353. PubMed ID: 28371438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon activation in primary Sjögren's syndrome: recent insights and future perspective as novel treatment target.
    Bodewes ILA; Versnel MA
    Expert Rev Clin Immunol; 2018 Oct; 14(10):817-829. PubMed ID: 30173581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A patient with primary Sjogren's syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review.
    Wise LM; Arkfeld DG
    Clin Rheumatol; 2020 Apr; 39(4):1357-1362. PubMed ID: 31863212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mobilization of lymphatic endothelial precursor cells and lymphatic neovascularization in primary Sjögren's syndrome.
    Alunno A; Ibba-Manneschi L; Bistoni O; Rosa I; Caterbi S; Gerli R; Manetti M
    J Cell Mol Med; 2016 Apr; 20(4):613-22. PubMed ID: 26828975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FcRL4
    Haacke EA; Bootsma H; Spijkervet FKL; Visser A; Vissink A; Kluin PM; Kroese FGM
    J Autoimmun; 2017 Jul; 81():90-98. PubMed ID: 28390747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologics in Sjögren's syndrome.
    Skarlis C; Marketos N; Mavragani CP
    Pharmacol Res; 2019 Sep; 147():104389. PubMed ID: 31415917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sjögren's syndrome].
    Seitz M
    Ther Umsch; 2008 May; 65(5):279-82. PubMed ID: 18622932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
    Akiyama M; Sasaki T; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):157-164. PubMed ID: 29465360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Issues related to clinical trials of oral and biologic disease-modifying agents for Sjögren's syndrome.
    Carsons SE
    Rheum Dis Clin North Am; 2008 Nov; 34(4):1011-23, x. PubMed ID: 18984419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of treatments for primary Sjögren's syndrome.
    van Nimwegen JF; Moerman RV; Sillevis Smitt N; Brouwer E; Bootsma H; Vissink A
    Expert Opin Drug Saf; 2016; 15(4):513-24. PubMed ID: 26809028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invariant NKT cells are expanded in peripheral blood but are undetectable in salivary glands of patients with primary Sjögren's syndrome.
    Guggino G; Ciccia F; Raimondo S; Giardina G; Alessandro R; Dieli F; Sireci G; Triolo G
    Clin Exp Rheumatol; 2016; 34(1):25-31. PubMed ID: 26633038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.